Here’s what you should know:
1. Takeda’s R&D efforts center on oncology, the central nervous system and gastroenterology.
2. In its Vision 2025 strategy, Takeda said the company’s resources would go towards R&D and its Japanese and U.S.-based developmental activities.
3. Datamonitor Healthcare Analyst Edward Thomason said to Chemistry World, in 2016 Takeda added seven programs to its pipeline and discontinued 12 others.
4. Mr. Thomason believes Takeda will continue rebuilding its pipeline through a series of external collaborations and acquisitions.
5. Over the last 18 months, Takeda formed more than 50 collaborations aimed at increasing its R&D presence.
More articles on gastroenterology:
GI center to know: Lakeside Endoscopy Center
PPIs included on list of drugs to ‘seriously consider deprescribing’
GI leader to know: Dr. Douglas Brouillette of Midwest Gastrointestinal Associates
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.